Listar por autor "Outeda, María"
Mostrando ítems 1-6 de 6
-
Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago
Elberdín, Laida; Fernández Torres, Rosa María; Paradela de la Morena, Sabela; Mateos, María; Blanco, Eva; Balboa-Barreiro, Vanesa; Gómez-Besteiro, María I.; Outeda, María; Martín-Herranz, Isabel; Fonseca, Eduardo (Springer, 2022-02-28)[Abstract] Introduction: The aim of this study was to evaluate response and drug survival of biologic therapy in patients with moderate to severe plaque-type psoriasis who initiated biologic therapy at least 10 years ago, ... -
Observational study to compare biological drug concentration quantification techniques and immunogenicity in patients with immune-mediated diseases
Martínez-Pradeda, Alejandro; Elberdín, Laida; Porta-Sánchez, Ángeles; Outeda, María; Diz-Lois Palomares, María Teresa; Vázquez-Rey, Teresa; González-Conde, Benito; Estévez-Prieto, Emilio; Gómez-Besteiro, María I.; Martín-Herranz, Isabel (MDPI, 2024-04-10)[Abstract] Measuring biological drugs' trough concentrations and the concentrations of anti-drug antibodies is a valuable practice for treatment optimization. ELISA techniques are the gold standard for biological drug ... -
Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week
Diz-Lois Palomares, María Teresa; Porta Sánchez, Ángeles; Elberdín, Laida; González Conde, Benito; Outeda, María; Vázquez-Rey, Teresa; Estévez-Prieto, Emilio; Martín-Herranz, Isabel; Alonso Aguirre, Pedro (Arán Ediciones, 2022)[Abstract] Background: Adalimumab dose escalation is often recommended for inflammatory bowel disease patients in cases of loss of response. The usual adalimumab intensification regimen was 40 mg every week. Recently the ... -
Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
Elberdín, Laida; Fernández Torres, Rosa María; Mateos, María; Outeda, María; Blanco, Eva; Gómez-Besteiro, María I.; Martín-Herranz, Isabel; Fonseca, Eduardo (Frontiers, 2022-12-08)[Abstract] Introduction: There is growing evidence that therapeutic drug monitoring of biologic therapy is beneficial in psoriatic patients. With respect to ustekinumab, the available evidence has not shown any relationship ... -
Results of the implementation of a pharmacogenomics platform based on NGS technologies: combining clinical and research approaches
Ramudo Cela, Luis; Busto-Fernández, Fernando; Outeda, María; Antolín, Silva; Calvo-Martínez, Lourdes; Martín-Herranz, Isabel (Sociedad Española de Farmacia Hospitalaria (SEFH), 2021)[Abstract] Objective: As more genes are incorporated into pharmacogenomic care processes and more importance is given to rare variants, the use of targeted capture sequencing panels has been proposed as a very efficient ... -
Tratamiento con sirolimus oral o tópico en anomalías vasculares complejas en pediatría: experiencia en un hospital terciario
Fernández Oliveira, Carla; Martínez Roca, Cristina; Gómez Tellado, Manuel; Salvador Garrido, María Pilar; Outeda, María; Martín-Herranz, Isabel (Sociedad Española de Cirugía Pediátrica, 2023)[Resumen] Objetivo. El uso de sirolimus en anomalías vasculares es una indicación especial no autorizada en ficha técnica. El objetivo de este estudio es incrementar la evidencia del empleo por vía oral o tópica de sirolimus ...
